Study of Oral Semaglutide for Treating Open-Angle Glaucoma Evaluating Safety and Retinal Function Improvement Over 6 Months

What this Trial Is About

Researchers are evaluating whether oral semaglutide can improve inner retinal function in people with open-angle glaucoma, a common eye condition. The study aims to find out if semaglutide safely enhances the photopic negative response measured by an electroretinogram. Participants will be compared between those taking semaglutide and those taking a placebo, a look-alike pill without the drug. Participants will take oral semaglutide or a placebo daily for six months. The semaglutide dosing starts at 3 mgday for the first month, increases to 7 mgday for the second month, then continues at 14 mgday for the remaining four months. The placebo group will take matching pills on the same schedule. The study involves five clinic visits at the start, and after 1, 2, 3, and 6 months. During these visits, participants will undergo tests including the electroretinogram, contrast sensitivity tests, and assessments of health-related quality of life. Researchers will also monitor treatment-related adverse events over the six months. The main outcome is the change in the electroretinogram response after six months compared to baseline. The total participation time lasts six months with regular monitoring.

A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma